Aptamer Group, a biotechnology company in York , has reported a forty per cent increase in revenues, supported by repeated business from several of the world’s top twenty pharmaceutical firms. The company, which manufactures synthetic binders used in medicine, diagnostic tests, and research tools, floated on AIM four years ago to take advantage of the potential of its Optimer binder technology.
The company has now released its full-year results for the period ending 30 June 2025. Revenues rose by forty per cent to £1.2 million, while its Ebitda losses decreased from ££2.8 million to £2.2 million. The cash balance at the year end was $£1.1$ million, an increase from £900,000 the previous year.
During the year, management stated that the company had shown progress, “both in terms of technical and financial development”. Key achievements included securing a contract with a top five pharmaceutical company for Optimer binder discovery and immunoassay development.
In July 2025, the firm successfully completed fundraising of £1.8 million, enhancing its financial strength. Furthermore, in the first quarter, it secured £675,000 in new contracts, supported by a £3.4 million sales pipeline.
Arron Tolley, CEO, commented: “This has been a year of strategic progress for Aptamer as we continued to expand the breadth and commercial reach of our Optimer platform. With a 40% increase in revenue and a growing base of repeat business from leading pharmaceutical partners. Our technology is gaining strong traction across life sciences and adjacent markets. We have more than doubled Aptamer’s portfolio of licensable Optimer assets from four to eleven, secured royalty-bearing agreements with Neuro-Bio and the University of Glasgow, and a global life science conglomerate. Additionally, we are in late-stage licensing negotiations for our enzyme-modulating assets, with two separate partners, which are expected to sign in the coming months.
“The expansion of our Unilever partnership, now including a second Optimer development programme, underlines the commercial strength and versatility of our platform technology. Looking ahead, the successful £1.8m fundraising completed after year-end provides the resources to accelerate our growth strategy, strengthen in-house manufacturing, and advance high-value Optimer programmes. With an expanding pipeline, deepening commercial relationships, and a robust financial position, we are well-placed to deliver long-term value for our shareholders.”
Image source: LinkedIn
